Predicting glioblastoma response to bevacizumab through marker profiling?

Neuro Oncol. 2016 Feb;18(2):149-50. doi: 10.1093/neuonc/nov320.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Bevacizumab*
  • Brain Neoplasms / drug therapy
  • Glioblastoma / drug therapy*
  • Humans
  • Neoplasm Recurrence, Local / drug therapy

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab